Valuation: Insmed Incorporated

Market Cap 24.7B 22.12B 20.35B 18.44B 34.46B 2,345B 35.11B 243B 97.4B 1,234B 92.69B 90.72B 3,890B P/E 2026 *
-71.6x
P/E 2027 * 165x
Enterprise Value 24.18B 21.66B 19.92B 18.05B 33.74B 2,296B 34.37B 238B 95.37B 1,208B 90.76B 88.83B 3,809B EV / Sales 2026 *
13x
EV / Sales 2027 * 7.98x
Free-Float
99.04%
Yield 2026 *
-
Yield 2027 * -
1 day+0.89%
1 week+20.55%
1 month-1.37%
3 months+14.18%
6 months-17.42%
Current year-35.31%
1 week 92.87
Extreme 92.87
116.37
1 month 92.62
Extreme 92.625
116.37
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 09/09/2012
Chief Tech/Sci/R&D Officer 62 18/12/2019
Chief Operating Officer 57 13/11/2019
Director TitleAgeSince
Chairman 75 15/06/2009
Chairman 57 07/11/2018
Director/Board Member 72 28/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Director

-25,000 0.0114%
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%+20.55%-40.62%+349.24% 24.7B
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
-1.29%-2.88%+22.87%-8.48% 23.27B
Average +0.18%+6.50%+45.11%+174.64% 41.76B
Weighted average by Cap. +0.10%+4.98%+46.59%+166.35%

Financials

2026 *2027 *
Net sales 1.86B 1.66B 1.53B 1.39B 2.59B 176B 2.64B 18.23B 7.32B 92.69B 6.96B 6.82B 292B 2.98B 2.67B 2.45B 2.22B 4.15B 283B 4.23B 29.24B 11.74B 149B 11.17B 10.93B 469B
Net income -362M -324M -298M -270M -505M -34.34B -514M -3.55B -1.43B -18.06B -1.36B -1.33B -56.97B 213M 191M 176M 159M 298M 20.26B 303M 2.1B 842M 10.66B 801M 784M 33.62B
Net Debt -514M -461M -424M -384M -718M -48.85B -731M -5.05B -2.03B -25.7B -1.93B -1.89B -81.03B -949M -850M -782M -708M -1.32B -90.11B -1.35B -9.32B -3.74B -47.4B -3.56B -3.49B -149B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
30/10/26 US$112.58 +0.89% 5,184,538
29/10/26 US$111.59 +15.06% 11,220,667
28/10/26 US$96.98 +2.13% 4,648,668
27/10/26 US$94.96 +1.75% 3,349,378
26/10/26 US$93.33 -0.06% 3,379,924
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
112.58USD
Average target price
193.95USD
Spread / Average Target
+72.28%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insmed Incorporated
  1. Stock Market
  2. Stocks
  3. INSM Stock